Replimune to Present at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

WOBURN, Mass., May 23, 2024 (GLOBE NEWSWIRE) -- Replimune Group Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel portfolio of oncolytic immunotherapies, today announced multiple presentations at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting being held in Chicago from May 31-June 4, 2024.

The Company has two abstracts selected for oral presentation, including an updated presentation of investigator-assessed 12-month data from the IGNYTE clinical trial of RP1 (vusolimogene oderparepvec) plus nivolumab in anti-PD-1 failed melanoma, and another presentation showcasing data from the Phase 1 trial of RP2 combined with nivolumab in advanced uveal melanoma. In addition, RP1 and RP2 are also featured in three trial-in-progress posters.

Details for the presentations are as follows:

Oral data presentations

Abstract Title: Efficacy and safety of RP1 combined with nivolumab in patients with anti-PD-1 failed melanoma from the IGNYTE clinical trial. Data included in the presentation will be 12-month investigator-assessed data with a cutoff date of March 8, 2024, as compared to the abstract which includes 6-month investigator-assessed data. As previously disclosed, the topline 12-month primary analysis results by independent central review are expected later in Q2 2024.

• Session Title: Melanoma/Skin Cancers
• Date: June 3, 2024; 10:57-11:03 AM CDT
• Location: S406
• Abstract: 9517

Abstract Title: Safety, efficacy, and biomarker results from an open-label, multicenter, phase 1 study of RP2 alone or combined with nivolumab in a cohort of patients with uveal melanoma.

• Session Title: Melanoma/Skin Cancers
• Date: June 3, 2024; 9:57-10:03 AM CDT
• Location: S406
• Abstract: 9511

Trial-in-progress poster presentations

Abstract Title: A randomized, controlled, multicenter, phase 3 study of vusolimogene oderparepvec (VO) combined with nivolumab vs treatment of physician’s choice in patients with advanced melanoma that has progressed on anti-PD-1 and anti-CTLA-4 therapy (IGNYTE-3).

• Poster Session Title: Melanoma/Skin Cancers
• Date: June 1, 2024, 1:30 PM-4:30 PM CDT
• Location: Hall A, Poster Board 385b
• Abstract: TPS9604

Abstract Title: An open-label, multicenter study investigating RP2 oncolytic immunotherapy in combination with second-line systemic atezolizumab combined with bevacizumab in patients with locally advanced unresectable or metastatic hepatocellular carcinoma